Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2014 6
2015 2
2016 10
2017 16
2018 22
2019 16
2020 29
2021 27
2022 14
2023 38
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.
Shafqat A, Elmaleh H, Mushtaq A, Firdous Z, Ashruf O, Mukhopadhyay D, Ahmad M, Ahmad M, Raza S, Anwer F. Shafqat A, et al. Among authors: anwer f. J Clin Med. 2024 Mar 18;13(6):1744. doi: 10.3390/jcm13061744. J Clin Med. 2024. PMID: 38541968 Free PMC article. Review.
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C. Gagelmann N, et al. Among authors: anwer f. J Clin Oncol. 2024 Feb 15:JCO2302232. doi: 10.1200/JCO.23.02232. Online ahead of print. J Clin Oncol. 2024. PMID: 38358946
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Dima D, Rashid A, Davis JA, Shune L, Abdallah AO, Li H, DeJarnette S, Khouri J, Williams L, Hashmi H, Raza S, McGuirk J, Anwer F, Ahmed N. Dima D, et al. Among authors: anwer f. Br J Haematol. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23. Br J Haematol. 2024. PMID: 38263627
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, Strouse C, Lochner J, Mahmoudjafari Z, Raza S, Valent J, Anderson LD Jr, Anwer F, Abdallah AO, Hashmi H. Dima D, et al. Among authors: anwer f. Transplant Cell Ther. 2024 Mar;30(3):308.e1-308.e13. doi: 10.1016/j.jtct.2023.12.016. Epub 2023 Dec 26. Transplant Cell Ther. 2024. PMID: 38151105
173 results